EUVIMEDEUVIMED entdecken
Crossref

FRONTIER—FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database—Evidence from Real-World Practice: Patients Using Intensive Insulin

Alexandria Ratzki-Leewing, Stewart B Harris, Rémi Rabasa-Lhoret iD, Yeesha Poon

Diabetes Technology & Therapeutics · 2025

DOI: 10.1089/dia.2024.0609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2025. Verfasst von Alexandria Ratzki-Leewing und 3 weiteren Autor:innen. Beteiligte Einrichtung: Western University, London, Canada. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Insulin, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus is associated with significant health care resource utilization (HCRU), partly due to acute complications, including diabetic ketoacidosis (DKA) and hypoglycemia.

Aim

To investigate glycated hemoglobin (HbA1c) levels and HCRU before and after adoption of FreeStyle Libre Systems (FSL) in people with diabetes on multiple daily injections of insulin (MDI).

Methods

This retrospective longitudinal study used administrative health data in Ontario, Canada, housed at IC/ES. The cohort comprised people with diabetes on MDI with a first FSL claim between September 16, 2019, and August 31, 2020 (index date), who remained on FSL for 24 months. HCRU (emergency department [ED] visits and hospitalization) was measured for 12 months before the index date and the last 12 months of follow-up. HbA1c data were taken from the last tests in each period.

Results

Mean HbA1c was statistically significantly reduced after FSL among people with type 1 diabetes mellitus (T1DM; n = 10,510; age 65 years, −0.1%; all P < 0.0001) or type 2 diabetes mellitus (T2DM; n = 12,668; age ≤65 years, −0.6%; >65 years, −0.3%; both P < 0.0001). Overall HCRU was statistically significantly reduced in the T1DM subgroups aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsInsulinDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansRetrospective StudiesFemaleMaleOntarioAdultMiddle AgedGlycated HemoglobinLongitudinal StudiesAgedDatabases, FactualYoung AdultBlood GlucoseHypoglycemiaPatient Acceptance of Health CareAdolescent

Stichwörter der Autor:innen

HbA1ccontinuous glucose monitoringdiabetic ketoacidosishealth care resource utilizationhypoglycemiainsulin therapy

Substanzen

Glycated HemoglobinHypoglycemic AgentsInsulinhemoglobin A1c protein, humanBlood Glucose

Autor:innen und Institutionen

  • Western University, London, Canada.
  • University of Maryland Institute for Health Computing, North Bethesda, Maryland, USA.
  • Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Montreal Clinical Research Institute, Montreal, Canada.
  • Abbott Diabetes Care, Mississauga, Canada.

ORCID-Profile: Rémi Rabasa-Lhoret

Zitieren

APA

Ratzki-Leewing, A., Harris, S. B., Rabasa-Lhoret, R., & Poon, Y. (2025). FRONTIER—FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database—Evidence from Real-World Practice: Patients Using Intensive Insulin. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2024.0609

Vancouver

Ratzki-Leewing A, Harris SB, Rabasa-Lhoret R, Poon Y. FRONTIER—FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database—Evidence from Real-World Practice: Patients Using Intensive Insulin. Diabetes Technology & Therapeutics. 2025. doi:10.1089/dia.2024.0609

BibTeX
@article{RatzkiLeewing2025,
  author = {Ratzki-Leewing, Alexandria and Harris, Stewart B and Rabasa-Lhoret, Rémi and Poon, Yeesha},
  title = {FRONTIER—FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database—Evidence from Real-World Practice: Patients Using Intensive Insulin},
  journal = {Diabetes Technology & Therapeutics},
  year = {2025},
  doi = {10.1089/dia.2024.0609}
}
Kostenlos starten →